ASH 2016: Updates of Clinical Trials In Hematological Malignancies

During the upcoming 58th annual meeting of the American Society of Hematology, to be held December 3 – 6 in San Diego, CA, multiple corporate and investigator presentations will be featured.  This overview (below) presents the key oral and poster presentations to be presented. Also read: ASH 2016: Informative and Clinical Useful.

Additional information and abstracts can be found online at the website of the American Society of Hematology.


AbstractTitlePresenterTypeTimeLocation
Saturday, December 3, 2016
104Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with RCHP as Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B-Cell Lymphoma. [Abstract]Lihua BuddeOral9:45 a.m.Room 7AB (San Diego Convention Center)
182Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T-Cell Lymphoma Versus Physician’s Choice (Methotrexate or Bexarotene): the Phase 3 ALCANZA Study. [Abstract]Youn KimOral2:15 p.m.Room 6AB (San Diego Convention Center)
211A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia. [Abstract]Harry ErbaOral4:00 p.m.San Diego Ballroom AB (Marriott Marquis San Diego Marina)
1606Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). [Abstract]Koji SasakiPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1645Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models. [Abstract]Scott PortwoodPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1646Tumor Specific Glycosylated CD43 Is a Novel and Highly Specific Target for Acute Myeloid Leukemia and Myelodysplastic Syndrome. [Abstract]Mette HazenbergPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1681FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML) [Abstract]Sophia AdamiaPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1834Safety and Activity of Brentuximab Vedotin plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory Classical Hodgkin Lymphoma: Initial Results of a Phase I/II Trial. [Abstract]Ryan CassadayPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1841ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity. [Abstract]Gordon NgPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1842Ninlaro (ixazomib) and Brentuximab Vedotin (ADCETRIS) Combination Results in Synergistic Antitumor Activity in Mouse Models of CD30 Positive Anaplastic Large Cell Lymphoma. [Abstract]Nibedita ChattopadhyayPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1853Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. [Abstract]Hervé TillyPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
1856Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. [Abstract]Andres Forero-TorresPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
2368Real World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Population. [Abstract]Neil JosephsonPoster5:30 -7:30 p.m.Hall GH (San Diego Convention Center)
Sunday, December 4, 2016
340A Phase 1b Study of Vadastuximab Talirine as Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia. [Abstract]Jay YangOral10:15 a.m.Pacific Ballroom (Marriott Marquis San Diego Marina)
384CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate. [Abstract]Daniel SherbenouOral1:15 p.m.Grand Hall B (Manchester Grand Hyatt San Diego)
464Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin’s Lymphoma (NHL). [Abstract]Arturo MolinaOral4:45 p.m.Room 5AB (San Diego Convention Center)
2832IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models. [Abstract]Sharlene AdamsPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
2993Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-cell Lymphomas. [Abstract]Michelle FanalePoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
3522Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care. [Abstract]Jennifer KahlerPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
3560The Use of a Novel CME Format to Elicit and Develop True Competence in Hematologist Ability to Risk Stratify Patients with Hodgkin Lymphoma. [Abstract]Patricia RepettoPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
3566Toxicity Burden of Bleomycin Treatment in Hodgkin Lymphoma: A Systematic Literature Review. [Abstract]Neil C JosephsonPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
Monday, December 5, 2016    
588Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. [Abstract]Koji SasakiOral8:15 a.m.Marriott Grand 2-4 (Marriott Marquis San Diego Marina)
590Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia. [Abstract]Dale BixbyOral7:15 a.m.San Diego Ballroom AB (Marriott Marquis San Diego Marina)
591Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients With Acute Myeloid Leukemia. [Abstract]Amir FathiOral7:30 a.m.San Diego Ballroom AB (Marriott Marquis San Diego Marina)
622Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. [Abstract]Tycel PhillipsOral7:45 a.m.Room 6B (San Diego Convention Center)
752Inhibition of MDR1 Overcomes Brentuximab Vedotin Resistance in Hodgkin Lymphoma Cell Line Model and Is Synergistic with Brentuximab Vedotin in Mouse Xenograft Model. [Abstract]Robert ChenOral10:45 a.m.Room 6CF (San Diego Convention Center)
768A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells. [Abstract]Yelena KovtunOral11:45 a.m.San Diego Ballroom AB (Marriott Marquis San Diego Marina)
1105Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. [Abstract]Alex HerreraOral4:30 p.m.Room 6B (San Diego Convention Center)
1106A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). [Abstract]Catherine DiefenbachOral4:45 p.m.Room 6B (San Diego Convention Center)
1109Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). [Abstract]Ramon Garcia-SanzOral5:30 p.m.Room 6B (San Diego Convention Center)
1148First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. [Abstract]Adam CohenOral4:45 p.m.Hall AB (San Diego Convention Center)
3958A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM). [Abstract]Thomas CardilloPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4126Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice. [Abstract]Aradhana AwasthiPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4144Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. [Abstract]Barbara ProPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4146A Phase I Trial of TGR-1202, a Next Generation Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma. [Abstract]Radhakrishnan RamchandrenPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4154A Phase 1/2 Clinical Trial of Brentuximab Vedotin and Bendamustine in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (Halo Study): Preliminary Report. [Abstract]Andrea GallaminiPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4176hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies. [Abstract]Francesca ZammarchiPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4177Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma. [Abstract]Heather Van EppsPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4187Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529. [Abstract]Francesco BertoniPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4194Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Study. [Abstract]Alex HerreraPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4225CD30 Expression Is Not Acquired at Time of Relapse in Diffuse Large B-Cell Lymphoma. [Abstract]Oscar CalzadaPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4465Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models. [Abstract]Mark LupherPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4470SGN-CD48A: A Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma. [Abstract]Tim LewisPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)
4486Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma. [Abstract]Kevin KellyPoster6:00 – 8:00 p.m.Hall GH (San Diego Convention Center)